指南与共识前列腺增生与排尿功能障碍

女性膀胱过度活动症治疗方式的短期获益与潜在危害:欧洲泌尿外科学会女性非神经源性下尿路症状指南小组主持的证据综述

What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel.
指南 / 共识 · Eur Urol · 2023-06-17

该综述由欧洲泌尿外科学会女性非神经源性下尿路症状指南小组主持,检索截至2022年5月的文献,评估女性膀胱过度活动症(OAB)各治疗方式的短期有效性、安全性与潜在危害。抗胆碱能药与β3受体激动剂多数结局优于安慰剂,β3受体激动剂减少夜尿更有效,抗胆碱能药不良事件显著更高。Onabot-A疗效优于安慰剂但急性尿潴留/清洁间歇自家导尿风险高6-8倍、尿路感染高2-3倍。骶神经刺激成功率显著高于抗胆碱能药(61% vs 42%,p=0.02)。

要点

  • 一线治疗包括抗胆碱能药、β3受体激动剂和胫后神经刺激。
  • 二线治疗包括Onabot-A膀胱注射或骶神经刺激。
  • 治疗选择应基于患者个体因素。

核心结论

  • 膀胱过度活动症是可管理的疾病,治疗选择应基于患者个体因素。

研究设计与样本

  • 由欧洲泌尿外科学会女性非神经源性下尿路症状指南小组主持的证据综述,检索Medline、Embase、Cochrane对照试验数据库及clinicaltrial.gov截至2022年5月的相关文献。
  • 采用Cochrane干预系统评价手册推荐工具评估偏倚风险,使用改良GRADE标准评估证据质量,并在适当情况下进行Meta分析。

主要发现

  • 抗胆碱能药和β3受体激动剂在多数结局上显著优于安慰剂,β3受体激动剂减少夜尿 episodes 更有效,抗胆碱能药不良事件显著更高。
  • Onabot-A在多数结局上优于安慰剂,但急性尿潴留/清洁间歇自家导尿率显著更高(6-8倍),尿路感染率显著更高(2-3倍)。
  • Onabot-A在治愈急迫性尿失禁(UUI)方面显著优于抗胆碱能药,但在减少平均UUI episodes方面无显著差异。
  • 骶神经刺激(SNS)成功率显著高于抗胆碱能药(61% vs 42%,p=0.02),不良事件发生率相似;SNS与Onabot-A在疗效结局上无显著差异。
  • Onabot-A满意度更高,但复发性尿路感染率更高(24% vs 10%);SNS与9%移除率和3%修正率相关。

关键数值与推荐

  • 一线治疗选项包括抗胆碱能药、β3受体激动剂和胫后神经刺激。
  • 二线选项包括Onabot-A膀胱注射或骶神经刺激。

临床怎么用

  • 所有患者应首先被告知并建议采取保守治疗措施。
  • 一线治疗选项包括抗胆碱能药或β3受体激动剂药物,以及胫后神经刺激操作。
  • 二线选项包括Onabot-A膀胱注射或骶神经刺激操作。
  • 治疗选择应基于患者个体因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Overactive bladder syndrome (OAB) is highly prevalent among women and has a negative impact on their quality of life. The current available treatments for OAB symptoms include conservative, pharmacological, or surgical modalities. OBJECTIVE: To provide an updated contemporary evidence document regarding OAB treatment options and determine the short-term effectiveness, safety, and potential harms of the available treatment modalities for women with OAB syndrome. EVIDENCE ACQUISITION: The Medline, Embase, and Cochrane controlled trial databases and clinicaltrial.gov were searched for all relevant publications up to May 2022. The risk of bias assessment followed the recommended tool in the Cochrane Handbook for Systematic Reviews of Interventions, and quality of evidence was assessed using the modified Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. A meta-analysis was performed where appropriate. EVIDENCE SYNTHESIS: Antimuscarinics and beta-3 agonists were significantly more effective than placebo across most outcomes, with beta-3 agonists being more effective at reducing nocturia episodes and antimuscarinics causing significantly higher adverse events. Onabotulinumtoxin-A (Onabot-A) was more effective than placebo across most outcomes, but with significantly higher rates of acute urinary retention/clean intermittent self-catheterisation (six to eight times) and urinary tract infections (UTIs; two to three times). Onabot-A was also significantly better than antimuscarinics in the cure of urgency urinary incontinence (UUI) but not in the reduction of mean UUI episodes. Success rates of sacral nerve stimulation (SNS) were significantly higher than those of antimuscarinics (61% vs 42%, p = 0.02), with similar rates of adverse events. SNS and Onabot-A were not significantly different in efficacy outcomes. Satisfaction rates were higher with Onabot-A, but with a higher rate of recurrent UTIs (24% vs 10%). SNS was associated with 9% removal rate and 3% revision rate. CONCLUSIONS: Overactive bladder is a manageable condition, with first-line treatment options including antimuscarinics, beta-3 agonists, and posterior tibial nerve stimulation. Second-line options include Onabot-A bladder injections or SNS. The choice of therapies should be guided by individual patient factors. PATIENT SUMMARY: Overactive bladder is a manageable condition. All patients should be informed and advised on conservative treatment measures in the first instance. The first-line treatment options for its management include antimuscarinics or beta-3 agonists medication, and posterior tibial nerve stimulation procedures. The second-line options include onabotulinumtoxin-A bladder injections or sacral nerve stimulation procedure. The therapy should be chosen based on individual patient factors.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Farag F, Sakalis VI, Arteaga SM, et al. What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel. Eur Urol. 2023. PMID: 37331921. doi:10.1016/j.eururo.2023.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。